Market Cap | 21.84B | P/E | 28.95 | EPS this Y | - | Ern Qtrly Grth | -33.70% |
Income | 1.11B | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 9.00% |
Sales | 16.4B | PEG | - | EPS past 5Y | - | 200D Avg Chg | -6.00% |
Dividend | 9.00% | Price/Book | 0.24 | EPS next 5Y | - | 52W High Chg | -29.00% |
Recommedations | - | Quick Ratio | 0.71 | Shares Outstanding | 0.99B | 52W Low Chg | 120.00% |
Insider Own | - | ROA | 4.02% | Shares Float | 198.70M | Beta | 0.61 |
Inst Own | 0.01% | ROE | 6.22% | Shares Shorted/Prior | -/- | Price | 22.00 |
Gross Margin | 78.60% | Profit Margin | 6.76% | Avg. Volume | 1,786 | Target Price | - |
Oper. Margin | 13.64% | Earnings Date | - | Volume | 7,539 | Change | 0.00% |
H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.
Leerink Swann | Market Perform | Nov 13, 18 |